Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $55.00 short call and a strike $60.00 long call offers a potential 5.49% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $55.00 by expiration. The full premium credit of $0.26 would be kept by the premium seller. The risk of $4.74 would be incurred if the stock rose above the $60.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 61.78 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Amgen Readies Cholesterol Drug After Results From Trial
Thu, 30 Jan 2014 23:56:22 GMT
Bloomberg – Amgen Inc. (AMGN) said it completed a fifth late-stage study of its experimental anti-cholesterol medicine, as it leads competitors trying to bring a new class of therapies to a market estimated to be worth billions. The new treatments target a protein called PCSK9 that’s associated with high levels of LDL, or “bad,” cholesterol. Amgen’s drug, evolocumab, met the study goals, enabling the company to proceed with an application for approval this year from regulators, Thousand Oaks, California-based Amgen said today in a statement. That puts Amgen, the world’s largest biotechnology company by revenue, ahead by six months to a year of its closest competitor in the drug class, a compound being developed by Sanofi (SAN) and Regeneron Pharmaceuticals Inc. (REGN), according to Eric Schmidt , an analyst with Cowen & Co. He estimates Amgen’s drug may target as many as 17 million patients in the U.S., Europe and Japan.
[$$] Lilly Profit Drops 12%
Thu, 30 Jan 2014 23:50:05 GMT
The Wall Street Journal – Eli Lilly's fourth-quarter earnings fell 12% as the drug maker entered a new round of patent expirations that will erode sales of top drugs throughout 2014.
Sanofi sues Eli Lilly over patents for top-selling insulin drug
Thu, 30 Jan 2014 23:15:23 GMT
Reuters – French drugmaker Sanofi sued Eli Lilly and Co on Thursday, alleging that the U.S. pharmaceutical company infringed patents on its top-selling diabetes treatment, the insulin product Lantus. The lawsuit, filed in United States District Court for the District of Delaware, was triggered by notification from Lilly last month that it applied with the U.S. Food and Drug Administration (FDA) seeking permission to sell a generic version of Lantus, known chemically as insulin glargine. Lilly, in its submission, challenged the validity of several patents on Lantus held by Sanofi.
6:33 am Eli Lilly reports EPS in-line, beats on revs; reaffirms FY14 guidance
Thu, 30 Jan 2014 20:57:36 GMT
Briefing.com – 6:33 am Eli Lilly reports EPS in-line, beats on revs; reaffirms FY14 guidance
Eli Lilly Beats on Earnings & Revs, Confirms View
Thu, 30 Jan 2014 19:40:03 GMT
Zacks – 2014 will be a challenging year for Eli Lilly with two major products – Cymbalta and Evista – facing generic competition this year.
Also on Market Tamer…
Follow Us on Facebook